Autologous Stem Cells in Pediatric Patients With Dilated Cardiomyopathy

NCT ID: NCT01504594

Last Updated: 2013-08-09

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

SUSPENDED

Clinical Phase

PHASE1

Total Enrollment

10 participants

Study Classification

INTERVENTIONAL

Study Start Date

2012-01-31

Study Completion Date

2013-08-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

The purpose of this study is to determine whether an autologous stem cell infusion through catheterism is safe and effective in the treatment of pediatric dilated cardiomyopathy.

Process:

1. Primary Evaluation

* Clinical History
* Echocardiogram to evaluate ejection fraction and other parameters
2. Signing of Informed Consent and clearing doubts
3. Bone Marrow stimulation for 3 consecutive days with G-CSF (Granulocyte Colony Stimulating Factor) applied subcutaneously
4. On the 4th day, in operation room and under sedation: Bone Marrow Harvest performed by hematologists through posterior iliac crests(amount calculated at 8cc/kg, without exceeding 150ml).
5. Recovery room with family members while the cells are being processed in the Hematology Laboratory.
6. Approximately 3 hours after the 1st procedure, the patient re-enters the operation room, which is equipped for cardiac catheterization, so that cardiologists infuse the stem cells through the femoral artery into the coronary arteries which irrigate the heart´s muscle fibers.
7. Patient goes back to the recovery area until the anesthesia effect is gone and can tolerate oral liquids.
8. Clinical and echocardiographic follow-ups at 6 weeks and 6 months after the procedure.

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

* The Patient will receive standard surgical care, accompanied by a nurse at all times.
* Premedication includes: Omeprazole (gastric protector), Ketorolac (anti-pain and swelling), ondansetron (antivomiting).

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Cardiomyopathy, Dilated

Keywords

Explore important study keywords that can help with search, categorization, and topic discovery.

Dilated cardiomyopathy Idiopathic Bone Marrow Stem Cells CD34 + Autologous

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

NA

Intervention Model

SINGLE_GROUP

Primary Study Purpose

TREATMENT

Blinding Strategy

NONE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Patients

Children which meet eligibility criteria and after being assessed, are stimulated with G-CSF, undergo bone marrow extraction and then have them applied directly to the coronary arteries through cardiac catheterization.

Group Type EXPERIMENTAL

Intracoronary autologous stem cell infusion

Intervention Type PROCEDURE

Under sedation and under sterile conditions in a fluoroscopy operation room, cardiac catheterization will be performed through the femoral artery to infuse the stem cells directly into the heart´s coronary arteries.

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Intracoronary autologous stem cell infusion

Under sedation and under sterile conditions in a fluoroscopy operation room, cardiac catheterization will be performed through the femoral artery to infuse the stem cells directly into the heart´s coronary arteries.

Intervention Type PROCEDURE

Other Intervention Names

Discover alternative or legacy names that may be used to describe the listed interventions across different sources.

Intracoronary CD34+ cell infusion

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Ejection fraction less than 35 percent in echocardiogram
* More than 3 months with complete medical treatment without significant improvement
* Complete medical treatment: digitalics, diuretics, vasodilators and beta blockers

Exclusion Criteria

* Not signing informed consent
* Active infection at enrolling time
* Inadequate G-CSF application
Minimum Eligible Age

1 Year

Maximum Eligible Age

16 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

Hospital Universitario Dr. Jose E. Gonzalez

OTHER

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Consuelo Mancias Guerra

Pediatric Hematology Professor

Responsibility Role PRINCIPAL_INVESTIGATOR

Principal Investigators

Learn about the lead researchers overseeing the trial and their institutional affiliations.

Consuelo Mancias, Hematologist

Role: STUDY_DIRECTOR

Hematology Service, University Hospital of Monterrey

Gerardo Sanchez, Cardiologist

Role: PRINCIPAL_INVESTIGATOR

Pediatrics Service, University Hospital of Monterrey

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

University Hospital Dr. Jose E. Gonzalez

Monterrey, N.l., Mexico

Site Status

Countries

Review the countries where the study has at least one active or historical site.

Mexico

Related Links

Access external resources that provide additional context or updates about the study.

http://www.medicina.uanl.mx/hu/

University Hospital Dr. Jose E. Gonzalez

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

HE-2012

Identifier Type: -

Identifier Source: org_study_id